stockrow
Monday 9 November 2026
Export EVMN’s income statement to Excel — free account
Evommune Inc.
EVMNEvommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024.
- EPS
- +89.9%
- Free cash flow
- +21.8%
Quarter to June 2026, against a year earlier
6.65
0.28
+4.40%
Follow EVMN
Alert me
| Dec '25 | Dec '24 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
Altman Z-Score |
1.47 | — |
P/S ratio |
0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
9.47 | (6.99) |
P/FCF ratio |
0.00 | 0.00 |
P/Operating CF |
(6.29) | (3.24) |
P/B ratio |
0.51 | 0.00 |
Price to Tangible BV |
0.51 | 0.00 |
EV/Sales |
0.00 | 0.00 |
EV/EBITDA |
0.55 | 0.67 |
EV/Operating CF |
0.58 | 0.57 |
EV/FCF |
0.57 | 0.57 |
Quick Ratio |
8.33 | 2.57 |
Current Ratio |
8.57 | 2.64 |
Net Debt/EBITDA |
1.87 | 1.04 |
Debt/Assets |
0.08% | 0.70% |
Debt/Equity |
0.00 | 0.01 |
Asset Turnover |
0.09 | 0.00 |
Operating CF/Net income |
1.11 | 0.85 |
Capex/Depreciation |
(0.17) | (0.07) |
| (224.59%) | 0.00% | |
| (45.76%) | 0.00% | |
ROIC |
(89.61%) | 0.00% |
Return on Tangible Assets |
(50.43%) | (144.31%) |
Average Days of Receivables |
0.00 | 0.00 |
Research and Development Expense of Revenue |
569.55% | 917.77% |
Selling, General and Administrative Expense of Revenue |
154.07% | 182.41% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
45.05% | 24.60% |
Graham Net Nets |
1.28 | (5.94) |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(162.30%) | (182.01%) |
Free Cash Flow Yield |
(73.06%) | (250.37%) |
Revenue per Share |
2.12 | 4.64 |
Operating CF per Share |
(12.46) | (38.59) |
Capex per Share |
(0.04) | (0.06) |
Free Cash Flow per Share |
(12.49) | (38.65) |
Cash per Share |
24.31 | 47.77 |
Shareholders Equity per Share |
33.50 | 31.52 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
33.50 | 31.52 |
Free Cash Flow |
(76.68) | (58.28) |
Working Capital |
135.57 | 46.01 |
Capital Expenditures |
(0.23) | (0.09) |
Net Current Asset Value |
134.10 | 45.47 |
EV/EBIT |
0.54 | 0.66 |
Capex to Sales |
0.02 | 0.01 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
1.40 | 0.97 |
Cash ROIC |
(21.60%) | (48.52%) |
Accounts Receivable Turnover |
0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Average Payables |
8.01 | — |
Average Assets |
150.50 | — |
Average Common Equity |
30.66 | — |
Columns are period end dates · fundamentals updated 25 Oct 2026